Pfizer Reports Second-Quarter 2009 Revenues of $11.0 Billion
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2009. Revenues were $11.0 billion, a decrease of 9% compared with the year-ago quarter and flat on a constant currency basis. Foreign exchange unfavorably impacted revenues by approximately $1.1 billion or 9%. For second-quarter 2009, U.S. revenues were $4.5 billion, a decrease of 5% compared with the year-ago quarter.
Xeloda in combination with oxaliplatin shown to be effective in early colon cancer
- Details
- Category: Roche
Roche has announced results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination with intravenous oxaliplatin (XELOX) immediately after surgery, which show that patients with colon cancer taking XELOX live disease free for longer compared to those taking the commonly used intravenous chemotherapy combination 5-fluorouracil/leucovorin (5-FU/LV).
Nycomed announces FDA filing for Daxas® in COPD
- Details
- Category: Nycomed
Nycomed has announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Daxas® as a once-daily oral treatment for patients with symptomatic COPD. The NDA submission is based on encouraging results from four Phase III trials of Daxas® (roflumilast) in the treatment of symptomatic COPD.
Novartis delivers strong operational performance in the first half of 2009
- Details
- Category: Novartis
- Pharmaceuticals an industry growth leader: Net sales up 12% (local currencies) in first half of 2009 on contributions from new products and expansion in all regions
- R&D maintains momentum: Anti-cancer therapy Afinitor introduced in the US, awaiting EU approval; new biologic Ilaris and OTC brand Prevacid 24HR gain US approvals; clinical trials set to start in July for A(H1N1) pandemic flu vaccine
- H1 2009 operating results advance well, but impacted negatively by currencies:
Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company's pending acquisition of Wyeth. The Commission's decision includes Pfizer's commitment to divest certain animal health assets in the EU.
Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer's Disease
- Details
- Category: Pfizer
Pfizer Inc has announced results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in combination with donepezil HCl tablets, in patients with Alzheimer's disease.(1,2) Based on the Phase 1 study results, PF-04360365 has advanced into Phase 2.(3)
GSK announces new commitments to fight HIV/AIDS in Sub-Saharan Africa
- Details
- Category: GlaxoSmithKline
Andrew Witty, Chief Executive Officer of GlaxoSmithKline, has announced a series of new initiatives targeted at improving research, development, and access to HIV/AIDS medicines for children in Sub-Saharan Africa and supporting healthcare for people living with HIV and AIDS.
More Pharma News ...
- Abbott and GSK to Collaborate on Molecular Diagnostic Test
- Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effientâ¢
- Bayer acquires exclusive rights to Bioton's insulin SciLin®
- Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial
- AstraZeneca to Advance AZD3480 in ADHD
- Bayer submits first-in-class estradiol-based oral contraceptive for approval in the US
- Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies